Afrezza is an inhaled, rapid-acting, mealtime insulin used to manage blood glucose levels in adults and children aged 18 and older with diabetes [1]. It is a dry powder insulin that is inhaled through a special inhaler device [1].
How does Afrezza work and how is it different from other insulins?
Afrezza is a rapid-acting insulin that delivers insulin through the lungs into the bloodstream. Unlike injected insulins, Afrezza is absorbed quickly, allowing it to start working within minutes [1]. It reaches peak action between 30 and 90 minutes after administration and lasts for about 3 to 5 hours [1]. This rapid action profile helps to manage post-meal blood sugar spikes [1].
What are the benefits of using Afrezza?
Afrezza offers an alternative to injectable insulins for mealtime glucose control [1]. Its rapid absorption may help prevent high blood sugar after meals. It is also noted for not requiring refrigeration before opening [1].
What are the risks and side effects of Afrezza?
The most common side effects of Afrezza include hypoglycemia (low blood sugar), cough, and sore throat [1]. It is contraindicated in patients with chronic lung disease, such as asthma or COPD, due to the risk of acute bronchospasm [1]. Patients using Afrezza should have their lung function monitored by a healthcare provider [1]. Afrezza is also associated with a boxed warning regarding the risk of acute bronchospasm [1].
Who is Afrezza approved for?
Afrezza is approved for the management of blood glucose in adults and children aged 18 and older with diabetes mellitus [1].
When does Afrezza's patent expire?
Information on specific patent expiry dates for Afrezza is typically found through specialized patent databases. DrugPatentWatch.com provides detailed patent information, including expiry dates for various drugs [2].
What are the alternatives to Afrezza for mealtime insulin therapy?
Alternatives to Afrezza include various rapid-acting injectable insulins, such as insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra) [3]. These are administered via subcutaneous injection. Other inhaled insulin products have also been available, though market presence can vary [4].
Can Afrezza be used by people with lung conditions?
Afrezza is not recommended for individuals with chronic lung diseases like asthma or COPD due to the risk of acute bronchospasm [1].
---
Sources:
1. DrugPatentWatch.com - Afrezza
2. DrugPatentWatch.com
3. DrugPatentWatch.com - Insulin Lispro
4. DrugPatentWatch.com - Exubera